CagriSema: Fixed-ratio combination of two separate molecules -- cagrilintide (long- acting amylin analog) and semaglutide (GLP-1 agonist) -- co-administered in a single weekly injection
HFpEF and Obesity and Recent or Recurrent Hospitalisation Patients with HFpEF, obesity and a history of recent HF decompensation (within the preceding 12 months) constituted a significant proportion of the populations in the STEP-HFpEF and SUMMIT trials
Nausea: Wegovy 2.4 mg: 44% (STEP 1) Zepbound 10 mg: 31% (SURMOUNT-1) Zepbound 15 mg: 36% (SURMOUNT-1) Tirzepatide produces modestly lower nausea rates at weight-loss-equivalent doses
Heres what most people experience during their treatment journey: Before Most people start glutathione IV therapy with concerns about dull, uneven skin tone, dark spots, hyperpigmentation, or low energy levels
A 2022 prospective cohort study found that low choline intake was associated with a higher risk of these conditions
The tissue under the tongue is highly vascular, with direct access to systemic circulation
